<div id="readability-page-1"><div><p>Genpact (G) is back in focus after a busy update, combining Q4 results that exceeded Wall Street expectations with 2026 guidance, a higher quarterly dividend, and ongoing share repurchases.</p> <p>See our latest analysis for Genpact.</p> <p>Even with the strong Q4 print, 2026 guidance and a higher dividend, Genpact's recent share price performance has been weak, with a 30 day share price return of 21.95% decline and a 1 year total shareholder return of 33.64% decline. This suggests momentum has been fading despite the fresh focus on AI led offerings and buybacks.</p> <p>If this update has you reassessing service and AI related names, it could be worth scanning the 59 profitable AI stocks that aren't just burning cash as a way to spot other cash generating AI exposed businesses.</p> <p>So with Genpact guiding to higher earnings, lifting its dividend and continuing buybacks while the share price has retreated, is the market offering a discount or already pricing in the company’s future AI led growth?</p> <h2>Most Popular Narrative: 25.6% Undervalued</h2> <p>Genpact's most followed narrative puts fair value at about $48.82 per share versus the last close at $36.31. This frames the current pullback as a sizeable gap to that estimate.</p> <blockquote> <p><em>Genpact's strong pipeline, particularly in high-growth verticals like high tech, manufacturing, and financial services, combined with increasing large-deal activity and stable operating leverage, sets the stage for above-sector-average revenue and EPS growth, aided by operating margin expansion and continued return of capital to shareholders.</em></p> </blockquote> <p><em>Read the complete narrative.</em></p> <p>Curious what earnings trajectory and margin profile sit behind that valuation gap? The narrative leans on steady top line progress, firmer profitability and a future P/E that stays below many service peers.</p> <p><strong>Result: Fair Value of $48.82 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, that 21.9% 30 day share price decline and management’s own comments on muted demand and slower legacy services show how easily this upbeat narrative could be knocked off course.</p> <p>Find out about the key risks to this Genpact narrative.</p> <h2> Build Your Own Genpact Narrative</h2> <p>If you see the story differently or just prefer to test the numbers yourself, you can build a custom Genpact view in minutes by starting with Do it your way.</p> <p>A great starting point for your Genpact research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.</p> <h2>Ready for more investment ideas?</h2> <p>If you stop with just one company, you could miss other opportunities. Use the Simply Wall Street Screener to quickly surface ideas that fit your style.</p> <ul> <li>Target value by scanning companies that look mispriced on quality and fundamentals with our 55 high quality undervalued stocks.</li> <li>Prioritize resilience by focusing on businesses with sturdy finances using the solid balance sheet and fundamentals stocks screener (45 results).</li> <li>Add income options by filtering for reliable payers with the 16 dividend fortresses.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

<p>Genpact (G) has reported Q4 results that surpassed Wall Street expectations, alongside a higher dividend and 2026 guidance. Despite this, the company's share price has declined by 21.95% over the past 30 days and 33.64% over the past year. Analysts suggest Genpact is undervalued, with a fair value estimate of $48.82 per share compared to its last close of $36.31. The company is focusing on AI-led growth and share buybacks, but risks remain due to muted demand in legacy services. Investors are encouraged to explore other profitable AI stocks as well.</p>

Genpact (G) Valuation Check After Q4 Beat Strong AI Demand And Higher Dividend Guidance